Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69,050 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects.
Li Z, Radin A, Li M, Hamilton JD, Kajiwara M, Davis JD, Takahashi Y, Hasegawa S, Ming JE, DiCioccio AT, Li Y, Kovalenko P, Lu Q, Ortemann-Renon C, Ardeleanu M, Swanson BN. Li Z, et al. Among authors: li y, li m. Clin Pharmacol Drug Dev. 2020 Aug;9(6):742-755. doi: 10.1002/cpdd.798. Epub 2020 Apr 29. Clin Pharmacol Drug Dev. 2020. PMID: 32348036 Free PMC article.
Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials.
Alexis AF, Rendon M, Silverberg JI, Pariser DM, Lockshin B, Griffiths CE, Weisman J, Wollenberg A, Chen Z, Davis JD, Li M, Eckert L, Gadkari A, Shumel B, Rossi AB, Graham NM, Ardeleanu M. Alexis AF, et al. Among authors: li m. J Drugs Dermatol. 2019 Aug 1;18(8):804-813. J Drugs Dermatol. 2019. PMID: 31424712 Clinical Trial.
Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension.
Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Hultsch T, Davis JD, Zhang Y, Zhu X, Chen Z, Li M, Ardeleanu M, Teper A, Akinlade B, Gadkari A, Eckert L, Kamal MA, Ruddy M, Graham NMH, Pirozzi G, Stahl N, DiCioccio AT, Bansal A. Cork MJ, et al. Among authors: li m. Br J Dermatol. 2020 Jan;182(1):85-96. doi: 10.1111/bjd.18476. Epub 2019 Oct 8. Br J Dermatol. 2020. PMID: 31595499 Free PMC article. Clinical Trial.
Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper.
Samineni D, Venkatakrishnan K, Othman AA, Pithavala YK, Poondru S, Patel C, Vaddady P, Ankrom W, Ramanujan S, Budha N, Wu M, Haddish-Berhane N, Fritsch H, Hussain A, Kanodia J, Li M, Li M, Melhem M, Parikh A, Upreti VV, Gupta N. Samineni D, et al. Among authors: li m. Clin Pharmacol Ther. 2024 May 16. doi: 10.1002/cpt.3298. Online ahead of print. Clin Pharmacol Ther. 2024. PMID: 38752712 Review.
Role of miRNAs in macrophage-mediated kidney injury.
Li J, Yan X, Wu Z, Shen J, Li Y, Zhao Y, Du F, Li M, Wu X, Chen Y, Xiao Z, Wang S. Li J, et al. Among authors: li m. Pediatr Nephrol. 2024 May 27. doi: 10.1007/s00467-024-06414-5. Online ahead of print. Pediatr Nephrol. 2024. PMID: 38801452 Review.
69,050 results
You have reached the last available page of results. Please see the User Guide for more information.